Kern Capital, LLC — Full Portfolio
21 tracked investments · listed companies and verified rows first
BiotechPalo Alto, US
Edward Pham(Executive Officer, Director)Jeffrey S. Glenn(Director)Menashe Elazar(Executive Officer, Director)Nancy Chang(Executive Officer)
PartnerJay Kern· solo GP
PartnerJay Kern· solo GP
Life sciences company acquired by Pacific Biosciences
PartnerJay Kern· solo GP
Co-investorsSamsung Catalyst Fund
BiotechLos Altos, US
John F. Donovan(Executive Officer, Director)Frank J. Bellizzi(Executive Officer)
BoardCraig Husfeld(Director)
PartnerJay Kern· solo GP
PartnerJay Kern· solo GP
Beverly Hills, US
John Wise(Executive Officer, Director)Colin Close(Executive Officer, Director)
BoardRichard Garman(Director)J.P. Whelan(Director)
PartnerJay Kern· solo GP
Co-investorsFTV CapitalMotive Partners
PartnerJay Kern· solo GP
BiotechThousand Oaks, US
Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)
BoardBeth Seidenberg(Director)inJim Tananbaum(Director)Deborah Palestrant(Director)inKevin Raidy(Director)
PartnerJay Kern· solo GP
Co-investorsForesite Capital5AM VenturesWestlake Village BioPartners
Cancer diagnostics company acquired by LabCorp
PartnerJay Kern· solo GP
Co-investorsCatalio Capital Management, LP
Pharmaceutical company acquired by Biogen
PartnerJay Kern· solo GP
Co-investorsFrazier Life SciencesSofinnova Ventures
Riboscience develops small-molecule therapeutics using ribose-based nucleoside chemistry and structure-guided design, focusing on oncology and virology.
BiotechHealthtech
PartnerJay Kern· solo GP
PartnerJay Kern· solo GP
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.